NEWS
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Champions Oncology (Nasdaq: CSBR) reported its financial results for Q4 and fiscal year 2024.
Q4 revenue increased 7% to $14 million, with an adjusted EBITDA income of $884,000.
However, annual revenue decreased 7% to $50.2 million, with a fiscal year 2024 adjusted EBITDA loss of $3.9 million.
The company faced challenges due to the biotech sector's funding environment and pharmaceutical spending patterns. Cost-cutting measures and operational efficiencies were implemented, showing positive results in Q4. Champions is optimistic about returning to consistent profitability in fiscal 2025.
The company ended Q4 with a cash position of $2.6 million and no debt.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1083Followers
68Following
7471Visitors
Follow